Treatment of patients with chronic hepatitis C who have not been previously treated;Traitement des malades atteints d'hépatite chronique C n'ayant jamais été traités

Gastroenterologie Clinique et Biologique

Volumn 26, Issue SPEC. 2, 2002, Pages

  Marcellin, Patrick ^a   Boyer, Nathalie ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; REBETRON; UNCLASSIFIED DRUG;

CHRONIC HEPATITIS; CONFERENCE PAPER; GENOTYPE; HEPATITIS C; HUMAN; PATIENT MONITORING; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036258832     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Traitement de l'hépatite C par l'interféron. Conférence de Consensus - Textes des experts. Comment traiter l'hépatite C?
2. The treatment of chronic viral hepatitis
3. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy
4. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
5. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C
6. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy
7. Hepatitis C virus infection: Side effects and quality of life
8. Interferon-alpha2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological evaluation
9. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: Quantitative assement by a morphometric method
10. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report
11. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
12. Interferon therapy in hepatitis C: Benefits and limitations
13. Use of high-dose interferon in the treatment of chronic hepatitis C
14. Treatment of chronic hepatitis C: Comparative virological response rates among the different interferons
15. Therapy of hepatitis C: Consensus interferon trials
16. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C
17. Factors affecting treatment responses to interferon-α in chronic hepatitis C
18. Hepatitis C virus genotypes in France: Relationship with epidemiology, pathogenicity and response to interferon therapy
19. Ribavirin treatment for chronic hepatitis C
20. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C
21. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo, controlled study
22. Rivabirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
23. A pilot study of combination therapy with ribarivin plus interferon alfa for interferon alfa-resistant chronic hepatitis C
24. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
25. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C
26. Randomised trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
27. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
28. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
29. EASL International Consensus Conference on Hepatitis C. Consensus Statement
30. Is an "A la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
31. L'interféron pegylé: Nouveau progrès dans le traitement de l'hépatite chronique C
32. Peginterferon alfa-2a in patients with chronic hepatitis C
33. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
34. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
35. Peginterferon alfa-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
36. Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study
37. Correlation of health related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 KDA) interferon alfa 2a (Pegasys) compared with standard interferon alfa 2a